Skip to Main Content

Hello, everyone, and how are you this morning? We are doing just fine, thank you, now that the Pharmalot campus has quieted down. The short people have departed for their respective destinations — the local schoolhouse and gainful employment — which leaves us alone with the official mascots in our respective corners. All of which means the time has come to get cracking. On that note, here are a few items of interest to help you along. Hope you have a smashing day and do keep us in mind if anything interesting arises …

Novo Nordisk (NOV) will cut 400 R&D jobs from Denmark and China in order to shift investment toward “biological and technological innovation.” The drug maker, which employs more than 42,000 people globally, has encountered pricing pressures, especially on its key diabetes franchise in the U.S. “Our analysis shows that we have a surplus of manual labor and are lacking competences in the digital sphere, informatics, data science, artificial intelligence and automations,” Novo Nordisk chief science officer Mads Krogsgaard Thomsen tells Reuters.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!